Extreme thrombocytosis under the treatment by amoxicillin/clavulanate

Yang, Chih‐Jen; Hwang, Jhi-Jhu; Chong, Inn‐Wen; Huang, Ming‐Shyan

doi:10.1007/s11096-006-9051-5

Cited by 11 publications

(11 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Secondary thrombosis can be seen due to drugs such as beta-lactam antibiotics, G-CSF, myconazole, vinco alkaloids, iron treatment, enoxaparin, antipsychotic drugs, adrenaline, glucocorticoid, retinoic acid and quinolons [5]. To the best of our knowledge, our patient is the first SMA patient to develop thrombocytosis with Nusinersen treatment.…”

mentioning

confidence: 77%

A Novel Adverse Event of Nusinersen Treatment: Thrombocytosis

et al. 2019

View full text Add to dashboard Cite

mentioning

confidence: 77%

A Novel Adverse Event of Nusinersen Treatment: Thrombocytosis

et al. 2019

View full text Add to dashboard Cite

“…There are few case reports of reactive thrombocytosis with beta-lactam and beta-lactamase inhibitor combination [4][5][6]. Augmentin-induced thrombocytosis is extremely rare with so far only one case report reported as per literature [7]. Res, Vol 10, Issue 5, 2017, 15-16 Balaji et al…”

Section: Discussionmentioning

confidence: 99%

Augmentin Induced Thrombocytosis: A Maiden Case Series

Balaji

Amita

Patil

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

When an infected patient suffers from thrombocytosis, it is very difficult to identify beta-lactam antibiotic-induced cases of the disease and separate those from the possibility that thrombocytosis is an acute-phase reaction in the infected patient. We present 3 cases who were treated with Augmentin for various indications and developed thrombocytosis during the treatment course. The Naranjo probability scale indicates Augmentin as the possible cause of the thrombocytosis in all our patients.

show abstract

“…15 To improve the application of the data to the Naranjo probability scale, adaptations were made by adding thrombocytosis-specific criteria to improve the grading of case reports for causality, as seen in Table 2. For the purpose of this review, reports of suspected thrombocytosis were systematically assessed for causality (Table 3 16-45 ). The following criteria will be utilized to assess causality of a drug by case report: number of cases described by independent investigators and the Naranjo score associated with causality.…”

Section: Methodsmentioning

confidence: 99%

A Review and Assessment of Drug-Induced Thrombocytosis

Thompson

2018

Ann Pharmacother

View full text Add to dashboard Cite

Objectives: The purpose of this article is to review the current literature on drug-induced thrombocytosis with the goal of critically assessing causality and providing a comprehensive review of the topic. Thrombopoietic growth factors, such as thrombopoietin-receptor agonists (romiplostim and eltrombopag) and erythropoietin are not included in our review. Data Sources: The literature search included published articles limited to the English language and humans in MEDLINE, EMBASE, and Web of Science databases. MEDLINE/PubMed (1966 to September 2018) was searched using the MeSH terms thrombocytosis/chemically-induced and thrombocytosis/etiology. EMBASE (1980 to September 2018) was searched using the EMTAGS thrombocytosis/side effect. Web of Science (1970 to September 2018) was searched using the search term thrombocytosis. References of all relevant articles were reviewed for additional citations and information. Study Selection and Data Extraction: Review articles, clinical trials, background data, case series, and case reports of drug-induced thrombocytosis were collected, and case reports were assessed for causality using a modified Naranjo nomogram. Data Synthesis: Drug-induced thrombocytosis, a form of reactive thrombocytosis cannot be easily differentiated from more common etiologies of reactive thrombocytosis. In all, 43 case reports of drug-induced thrombocytosis from a wide variety of drugs and drug classes were reviewed using a modified Naranjo probability scale that included criteria specific for thrombocytosis. Conclusions: Drug-induced thrombocytosis is a relatively rare adverse drug reaction. The strongest evidence of causality supports low-molecular-weight heparins and neonatal drug withdrawal. Weaker evidence exists for all-trans retinoic acid, antibiotics, clozapine, epinephrine, gemcitabine, and vinca alkaloids.

show abstract

Extreme thrombocytosis under the treatment by amoxicillin/clavulanate

Cited by 11 publications

References 9 publications

A Novel Adverse Event of Nusinersen Treatment: Thrombocytosis

A Novel Adverse Event of Nusinersen Treatment: Thrombocytosis

Augmentin Induced Thrombocytosis: A Maiden Case Series

A Review and Assessment of Drug-Induced Thrombocytosis

Contact Info

Product

Resources

About